Skip to main content

Medications

Medications

Doctor holding virtual heart in hand. - healthcare concept

07-12-2022 | Rheumatoid arthritis | News

Similar reduction in CV risk with different add-on RA treatments

Among patients with active rheumatoid arthritis, adding tumor necrosis factor inhibitors to methotrexate is associated with a similar reduction in vascular inflammation to that seen with add-on sulfasalazine plus hydroxychloroquine, suggest findings from a randomized controlled trial.

16-11-2022 | ACR 2022 | Conference coverage | News

PD-1 receptor agonist may represent a novel treatment for patients with RA

Peresolimab, a PD-1 receptor agonist, may represent a promising approach to treating rheumatoid arthritis, with an “encouraging” safety profile, suggests research reported at the ACR Convergence 2022 in Philadelphia, Pennsylvania, USA.

27-10-2022 | Rheumatoid arthritis | News

ESR, DAS28 may impact RA trajectory during biologic or targeted therapy

Baseline erythrocyte sedimentation rate and DAS28 may be the strongest predictors of disease trajectory in patients with rheumatoid arthritis that does not respond to conventional DMARD therapy, suggest researchers from South Korea.

Analyzing samples concept - close up of pipette and test tubes

11-10-2022 | Rheumatoid arthritis | News

Serum calprotectin could indicate inflammatory activity in tocilizumab-treated RA patients

Serum calprotectin levels could represent a useful biomarker of inflammation in people with rheumatoid arthritis treated with the IL-6 receptor inhibitor tocilizumab, research suggests.

Doctor holds a two puzzle pieces with gender symbols

30-09-2022 | Rheumatoid arthritis | News

Study identifies sex differences in RA remission rates

Men with rheumatoid arthritis initiating treatment with biologic or targeted synthetic DMARDs may be more likely to achieve remission than women, suggests research reported at The Lancet Summit: Sex and gender in rheumatology.

12-09-2022 | Methotrexate | News

Methotrexate side effects more common in PsA than RA

People initiating methotrexate for psoriatic arthritis report significantly more side effects during the first year of treatment than those given the drug for rheumatoid arthritis, US research shows.

19-08-2022 | Rheumatoid arthritis | News

Caution needed with hydroxychloroquine use in older RA patients with heart failure

Hydroxychloroquine is not associated with an overall increased risk for sudden cardiac arrest or ventricular arrhythmia or major adverse cardiovascular events relative to methotrexate among older people with rheumatoid arthritis, study findings suggest.

05-08-2022 | Biologics | News

Support for long-term use of biologics in people with HIV

TNF inhibitors have good long-term effectiveness and are well tolerated in HIV-positive individuals with rheumatic diseases, researchers report.

Mid section of pregnant woman standing in corridor of hospital (symbolic image with model)

28-07-2022 | Rheumatoid arthritis | News

TNF inhibitor use during pregnancy linked to higher infant birthweight

Tumor necrosis factor inhibitor use by pregnant women with well-controlled rheumatoid arthritis is associated with a reduced risk for having a child that is born small for gestational age, study findings indicate.

12-07-2022 | Rheumatoid arthritis | News

Background methotrexate may boost placebo response in RA trials

Background therapy with methotrexate may partly explain placebo responses observed in rheumatoid arthritis clinical trials, study findings indicate.

Close up of man with psoriasis on the arm and abdomen

08-07-2022 | Rheumatoid arthritis | News

TNF inhibitors linked to higher psoriasis risk than other RA treatments

Treatment with TNF inhibitors is associated with a twofold increased risk for new-onset psoriasis compared with nonbiologic agents, suggest findings from a Danish cohort study.

04-07-2022 | Rheumatoid arthritis | News

Ozoralizumab shows promise in methotrexate-resistant RA

The next-generation anti-tumor necrosis factor-alpha antibody ozoralizumab significantly improves clinical signs and symptoms of rheumatoid arthritis relative to placebo in people with active disease despite methotrexate therapy, research suggests.

Antibodies, immunoglobulin proteins, Immune system. 3D rendering

30-06-2022 | COVID-19 | News

VROOM trial: Pausing methotrexate doubles antibody response to COVID-19 booster vaccine

Holding methotrexate treatment for 2 weeks following administration of a booster dose of vaccines against SARS-CoV-2 significantly improves the humoral immune response to vaccination, suggest findings from a randomized controlled trial.

21-06-2022 | Glucocorticoids | News

Low-dose glucocorticoids show no negative impact on BMD

Low glucocorticoid doses are not associated with reduced bone mineral density in people with inflammatory rheumatic and musculoskeletal diseases, observational study findings indicate.

16-06-2022 | Rheumatoid arthritis | News

Targeted therapy not linked to serious infection risk in older people with RA

Older people with rheumatoid arthritis are not at increased risk for hospitalization with infection when receiving targeted therapy with biologics or JAK inhibitors rather than methotrexate, Japanese researchers report.

Scientists working in a genetic research laboratory

15-06-2022 | Rheumatoid arthritis | News

Molecular signatures could help guide RA treatment selection

An in-depth molecular analysis of synovial biopsies from people with rheumatoid arthritis who participated in the R4RA trial has identified gene signatures associated with treatment response.

09-06-2022 | EULAR 2022 | Conference coverage | News

Reduced methotrexate dose noninferior to higher dose at adalimumab initiation in RA

Findings from the MIRACLE study indicate that patients with rheumatoid arthritis and inadequate response to methotrexate who receive a reduced dose of methotrexate at adalimumab initiation have comparable remission outcomes to those given the maximum tolerable dose, and may have fewer adverse events.

06-06-2022 | EULAR 2022 | Conference coverage | News

DMARD treatment has ‘profound anticoagulant effects’ in early RA

Analysis of data from the NORD-STAR study suggests that people with early rheumatoid arthritis have increased levels of coagulation biomarkers, putting them at increased risk for venous thromboembolism, and initial treatment with DMARDs can help reduce this imbalance.

Covid-19 vaccine vial and needle

04-06-2022 | EULAR 2022 | Conference coverage | News

Support for pausing methotrexate only after second COVID-19 vaccine dose

Pausing methotrexate only after the second dose of a COVID-19 vaccine may provide the best balance between antibody response and risk for flare, findings from two randomized controlled trials suggest.